Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Annals of the Rheumatic Diseases

Volumn 75, Issue 2, 2016, Pages 396-401

  Mohammad, A J ^a   Hot, A ^a   Arndt, F ^a   Moosig, F ^a   Guerry, M J ^a   Amudala, N ^a   Smith, R ^a   Sivasothy, P ^a   Guillevin, L ^a   Merkel, P A ^a   Jayne, D R W ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ACHILLES TENDON RUPTURE; ADULT; AGED; ARTICLE; ASTHMA; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CHEST INFECTION; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CONFUSION; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; EPILEPSY; EUROPE; FEMALE; HUMAN; HYPOCALCEMIA; IMMUNOGLOBULIN DEFICIENCY; JOINT STIFFNESS; LEUKOPENIA; MALE; PRIORITY JOURNAL; PUSTULOSIS; PYELONEPHRITIS; RASH; RELAPSE; REMISSION; THYMOMA; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; BLOOD; CHURG-STRAUSS SYNDROME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TIME FACTOR;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHURG-STRAUSS SYNDROME; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PREDNISOLONE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RITUXIMAB; TIME FACTORS;

EID: 84954165832     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206095     Document Type: Article

References (31)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11
2. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52:2926-35
3. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951;27:277-301
4. Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013;65:270-81
5. Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011;90:19-27
6. Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000;43:414-19
7. Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J 2008;38:816-23
8. Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004;51:92-9
9. Mohammad AJ, Jacobsson LT, Mahr AD, et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007;46:1329-37
10. Herlyn K, Buckert F, Gross WL, et al. Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford) 2014;53:882-9
11. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-17
12. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100
13. Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008;58:586-94
14. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20
15. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32
16. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006;65:557-9
17. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006;65:1116-17
18. Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008;47:1104-5
19. Saech J, Owczarczyk K, Rosgen S, et al. Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 2010;69:1254-5
20. Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011;26:2865-71
21. Donvik KK, Omdal R. Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int 2011;31:89-91
22. Martinez-Villaescusa M, Lopez-Montes A, Lopez-Rubio E, et al. Treatment-resistant Churg-Strauss syndrome: progression after five years using rituximab. Nefrologia 2013;33:737-9
23. Thiel J, Hassler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 2013;15:R133
24. Umezawa N, Kohsaka H, Nanki T, et al. Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG. Mod Rheumatol 2014;24:685-7
25. Vaglio A, Moosig F, Zwerina J. Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol 2012;24:24-30
26. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-100
27. de Groot K, Gross WL, Herlyn K, et al. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8
28. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32
29. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3760-9
30. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7
31. Keogh KA, Wylam ME, Stone JH, et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8.